CTOR Citius Oncology Inc Forecast, Technical & Fundamental Analysis

CTOR's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for CTOR moved out of oversold territory on November 25, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 7 similar instances when the indicator left oversold territory. In of the 7 cases the stock moved higher. This puts the odds of a move higher at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 18, 2025. You may want to consider a long position or call options on CTOR as a result. In of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CTOR just turned positive on November 28, 2025. Looking at past instances where CTOR's MACD turned positive, the stock continued to rise in of 28 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CTOR advanced for three days, in of 76 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 32 cases where CTOR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CTOR moved below its 50-day moving average on December 02, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for CTOR moved below the 200-day moving average on December 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTOR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTOR broke above its upper Bollinger Band on December 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CTOR entered a downward trend on December 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.164) is normal, around the industry mean (24.311). P/E Ratio (0.000) is within average values for comparable stocks, (74.353). CTOR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.954). CTOR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.000) is also within normal values, averaging (64.216).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CTOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.